MID-VOLUME · HOSP-HEAVY
linagliptin Side Effects
linagliptin (also sold as Tradjenta) sits MID-VOLUME #253 of 524 by FAERS report count. Lead signal: HOSP-HEAVY - 37.6% mention hospitalization (6,542 reports). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 17,378
- FAERS reports
FDA Adverse Event Reporting System extract for linagliptin. Stamp set WATCHLIST · DEATH-HEAVY · HOSP-HEAVY. How figures are compiled.
linagliptin: 37.6% mention hospitalization (6,542 reports). Death stamp DEATH-HEAVY; volume band MID-VOLUME #253 of 524 by FAERS report count.
Mid-book FAERS page for linagliptin (Tradjenta) (17,378 reports). Signature HOSP-HEAVY. Dominant age band on file: 75+. Educational reference only.
Counts from the openFDA FAERS extract (2006–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
BLOOD GLUCOSE INCREASED leads 1,326 of 17,378 reports
Who reports · age peak 75+ (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 75+ (4,362 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (1,613 reports, 9.3%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 545 |
| ACUTE KIDNEY INJURY | 118 |
| RENAL FAILURE | 85 |
| PNEUMONIA | 83 |
| DYSPNOEA | 75 |
| DIARRHOEA | 61 |
| URINARY TRACT INFECTION | 60 |
| CARDIAC ARREST | 59 |
| SEPSIS | 56 |
| VOMITING | 56 |
| DECREASED APPETITE | 50 |
| CHRONIC KIDNEY DISEASE | 49 |
| CONDITION AGGRAVATED | 48 |
| FALL | 48 |
| CARDIAC FAILURE | 46 |
| CEREBROVASCULAR ACCIDENT | 46 |
| ASTHENIA | 43 |
| DISEASE PROGRESSION | 43 |
| CARDIAC FAILURE CONGESTIVE | 42 |
Reactions in Hospitalization Reports
Hospitalization is HEAVY (6,542, 37.6% of the book). Top reactions in those rows:
| Reaction | Reports |
|---|---|
| ACUTE KIDNEY INJURY | 543 |
| DYSPNOEA | 475 |
| DIARRHOEA | 442 |
| VOMITING | 402 |
| FATIGUE | 395 |
| FALL | 385 |
| PNEUMONIA | 380 |
| NAUSEA | 379 |
| PYREXIA | 351 |
| BLOOD GLUCOSE INCREASED | 325 |
| DIZZINESS | 320 |
| MALAISE | 306 |
| DEHYDRATION | 301 |
| ASTHENIA | 280 |
| RENAL FAILURE | 262 |
| URINARY TRACT INFECTION | 247 |
| CHEST PAIN | 234 |
| HYPOTENSION | 233 |
| HEADACHE | 226 |
How to read linagliptin FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-HEAVY)
FAERS holds 17,378 voluntary reports linked to linagliptin (Tradjenta), 2006-2025. Death is listed on 1,613 (9.3%). Hospitalization appears on 6,542 (37.6%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-HEAVY · HOSP-HEAVY as signal-detection rates next to 37.6% mention hospitalization (6,542 reports).
Read with linagliptin
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-HEAVY stamps.
ABS(total_reports) peer at 17,328 FAERS cases (Δ 50 lighter vs linagliptin); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 17,512 FAERS cases (Δ 134 heavier vs linagliptin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 17,199 FAERS cases (Δ 179 lighter vs linagliptin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 17,186 FAERS cases (Δ 192 lighter vs linagliptin); DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 52.8 pp vs linagliptin's DEATH-HEAVY): CASELOAD · HOSP-MID.
linagliptin stamps DEATH-HEAVY · HOSP-HEAVY; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.